Kyntra Bio Overview

  • Year Founded
  • 1993

Year Founded

  • Status
  • Public

  • Employees
  • 34

Employees

  • Stock Symbol
  • KYNB

Stock Symbol

  • Share Price
  • $1.59
  • (As of Friday Closing)

Kyntra Bio General Information

Description

Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.

Contact Information

Formerly Known As
FibroGen
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 350 Bay Street
  • Suite 100 Number 6009
  • San Francisco, CA 94133
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 350 Bay Street
  • Suite 100 Number 6009
  • San Francisco, CA 94133
  • United States
+1 (415)

Kyntra Bio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Kyntra Bio Stock Performance

As of 20-Nov-2026, Kyntra Bio’s stock price is $1.59. Its current market cap is $6.32M with 4.05M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.59 $1.83 $1.56 - $10.47 $6.32M 4.05M 30.2K -$4.27

Kyntra Bio Financials Summary

As of 30-Sep-2026, Kyntra Bio has a trailing 12-month revenue of $5.3M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV (42,391) (47,943) 43,659 91,471
Revenue 5,303 6,440 29,621 46,803
EBITDA (12,791) (51,730) (147,724) (312,791)
Net Income (17,287) 183,452 (47,579) (284,232)
Total Assets 48,851 119,594 214,525 423,529
Total Debt 0 0 73,092 149,614
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Kyntra Bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Kyntra Bio‘s full profile, request access.

Request a free trial

Kyntra Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease
Drug Discovery
San Francisco, CA
34 As of 2025

San Francisco, CA
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Kyntra Bio Competitors (40)

One of Kyntra Bio’s 40 competitors is Pliant Therapeutics, a Formerly VC-backed company based in San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pliant Therapeutics Formerly VC-backed San Francisco, CA
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Minerva Neurosciences Formerly VC-backed Burlington, MA
Verona Pharma Corporate Backed or Acquired London, United Kingdom
Rein Therapeutics Formerly VC-backed Austin, TX
You’re viewing 5 of 40 competitors. Get the full list »

Kyntra Bio Patents

Kyntra Bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024383235-A1 [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) Pending 22-Nov-2023
WO-2025111214-A1 [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3- carbonyl)amino]acetic acid (roxadustat) for the treatment of anemia in subjects with myelodysplastic syndrome (mds) Inactive 22-Nov-2023
WO-2024238207-A1 [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (cia) Inactive 17-May-2023
WO-2024226713-A2 Solid [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino] acetic acid Inactive 28-Apr-2023
WO-2024226713-A3 Solid [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino] acetic acid Inactive 28-Apr-2023 A61K9/2018
To view Kyntra Bio’s complete patent history, request access »

Kyntra Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Kyntra Bio ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.28 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Kyntra Bio’s complete esg history, request access »

Kyntra Bio FAQs

  • When was Kyntra Bio founded?

    Kyntra Bio was founded in 1993.

  • Where is Kyntra Bio headquartered?

    Kyntra Bio is headquartered in San Francisco, CA.

  • What is the size of Kyntra Bio?

    Kyntra Bio has 34 total employees.

  • What industry is Kyntra Bio in?

    Kyntra Bio’s primary industry is Drug Discovery.

  • Is Kyntra Bio a private or public company?

    Kyntra Bio is a Public company.

  • What is Kyntra Bio’s stock symbol?

    The ticker symbol for Kyntra Bio is KYNB.

  • What is the current stock price of Kyntra Bio?

    As of 20-Nov-2026 the stock price of Kyntra Bio is $1.59.

  • What is the current market cap of Kyntra Bio?

    The current market capitalization of Kyntra Bio is $6.32M.

  • What is Kyntra Bio’s current revenue?

    The trailing twelve month revenue for Kyntra Bio is $5.3M.

  • Who are Kyntra Bio’s competitors?

    Pliant Therapeutics, Sarepta Therapeutics, Minerva Neurosciences, Verona Pharma, and Rein Therapeutics are some of the 40 competitors of Kyntra Bio.

  • What is Kyntra Bio’s annual earnings per share (EPS)?

    Kyntra Bio’s EPS for 12 months was -$4.27.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process